Clinical Study | Office of Clinical Research

A Phase 3 Trial Of Pembrolizumab (Mk-3475) Vs Standard Treatment In Recurrent/Metastatic Head And Neck Cancer

Posted Date: May 15, 2019

Investigator: John Morris
Type of Study: Drug

The purpose of this study is to test the safety, tolerability and anti-tumor activity of the research study drug, pembrolizumab (MK-3475) and to test the effectiveness of the research study drug pembrolizumab compared to standard treatment (methotrexate, docetaxel or cetuximab) for recurrent or meta

Criteria:

To Be Eligible To Participate, Patients Must Have Been Diagnosed With Recurrent Or Metastatic Head A

Keywords:

Cancer, Mk3475-040, Recurrent, Metastatic, Head & Neck

For More Information:

Uc Cancer Center
513-584-7698
kastla@uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List